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Abstract: 
We have performed molecular docking on quinazoline antifolates complexed with human thymidylate synthase to gain insight into the structural 
preferences of these inhibitors. The study was conducted on a selected set of one hundred six compounds with variation in structure and activity. 
The structural analyses indicate that the coordinate bond interactions, the hydrogen bond interactions, the van der Waals interactions as well as 
the hydrophobic interactions between ligand and receptor are responsible simultaneously for the preference of inhibition and potency. In this 
study, fast flexible docking simulations were performed on quinazoline antifolates derivatives as human thymidylate synthase inhibitors. The 
results indicated that the quinazoline ring of the inhibitors forms hydrophobic contacts with Leu192, Leu221 and Tyr258 and stacking interaction 
is conserved in complex with the inhibitor and cofactor.   
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Background: 
Thymidylate synthase has been a primary target for chemotherapy 
aimed at cancers of the gastrointestinal tract and head and neck [1] 
despite
  moderate response in 30-40% of patients. Thymidylate 
synthase has been favorite target for designing and developing 
inhibitors which could be used as anticancer drugs [2]. A major 
problem affecting
 TS-directed treatments is that tumor cells often react 
to an exposure
 to Thymidylate synthase inhibitors by raising levels of 
intracellular TS activity
  about 2-  to 4-fold, which may lead to 
resistance.  Thymidylate synthase (TS) catalyzes the reductive 
methylation of 2'-deoxyuridine 5'-monophosphate (dUMP) to 
thymidine 5'-monophosphate
  (dTMP), using the co-substrate, 5,10-
methylenetetrahydrofolate
  (CH2H4folate) as a one-carbon donor and 
reductant. The physical
 structures of bacterial TSs have been relatively 
well defined,
 and crystallographic data, in concert with data derived 
from kinetic,
  spectroscopic, and site-directed mutagenesis studies, 
have led
  to a detailed understanding of the catalytic mechanism of 
these
  enzymes  [3]. In contrast, relatively few investigations of
 
mammalian TS structure and catalysis have been conducted. The
 three-
dimensional structure of the native human thymidylate synthase (hTS) 
has been
 reported previously [4]. The data showed a surprising feature
 
not observed in TSs from other sources: loop 181-197 containing
 the 
catalytic cysteine, Cys-195, was in an inactive conformation,
  and 
rotated ~ 180° with respect to its orientation in bacterial TSs,
 with the 
sulfhydryl of Cys-195 over 10 Å from the location of
 sulfhydryls of 
corresponding cysteine residues in bacterial enzymes.
  Subsequent 
determination of the structure of a ternary inhibitory
 complex between 
closely related ratTS (rTS) and dUMP and tomudex
 [5] has shown that 
the ligands bind to the enzyme in the active
 conformation. Recently, it 
was found that also in the hTS·dUMP·tomudex
 complex hTS is in the 
active conformation. The inactive
 conformation has not been observed 
in TSs other than
 human [6].  
 
Although T S does not represent a new target, there is still enthusiasm 
for the development of quinazoline derivatives. A unique feature of TS 
is the selectivity that is possible in the design of inhibitors. This makes 
it an ideal “old” target for rational and effective drug design for 
anticancer agents. Nowadays, molecular docking approaches are 
routinely used in modern drug design to help understand drug–receptor 
interaction. It has been shown in the literature that these computational 
techniques can strongly support and help the design of novel, more 
potent inhibitors by revealing the mechanism of drug–-receptor 
interaction [7]. However, so far, there has been no report concerning 
the application of molecular docking methodology for understanding 
the binding of quinazoline antifolate derivatives. The antifolate 
compounds evaluated in this investigation are derivatives of 
quinazoline antifolate, having structures similar to the 
tomudex/ZD1694 class of antifolates, where quinazoline is a 
compound made up of two fused six-membered simple aromatic ring, 
a benzene ring and a pyrimidine ring. Its chemical formula is C8H6N2. 
Due to an interest in new anticancer drugs, several quinazoline 
antifolate inhibitors were chosen from the ICI Pharmaceutical & 
Institute of Cancer Research, England for screening against human 
thymidylate synthase [8–11].  
 
Molecular docking is a key tool in structural molecular biology and 
computer-assisted drug design. The goal of ligand—protein docking is 
to predict the predominant binding model(s) of a ligand with a protein 
of known three-dimensional structure. In this study, we have used fast 
flexible docking to study the binding orientations and predict binding 
affinities of quinazoline antifolate derivatives. Such studies have been 
carried out to understand the forms of interaction of one hundred six 
compounds, sysnthesized by Marsham et al [8-11]  for the human 
thymidylate synthase. The results obtained from this study would be 
useful in both understanding the inhibitory mode of quinazoline 
antifolate derivatives as well as in rapidly and accurately predicting the 
activities of newly designed inhibitors on the basis of docking scores. 
These models also provide some beneficial clues in structural 
modification for designing new inhibitors for the treatment of cancer 
with much higher inhibitory activities against thymidylate synthase. 
 
Methodology: 
Molecular structures & optimization 
The biological activity data of quinazoline antifolate derivatives (one 
hundred six compounds), reported by Marsham et al [8-11] was used 
in the present study shown in Table 1. The structures of all the 
compounds were constructed using the InsightII 2000.1 Builder 
module (http://www.accelrys.com). The geometries of these 
compounds were subsequently optimized using Discover module of 
InsightII 2000.1 using CVFF force field. The structure of humanTS 
protein (PDBid code 1I00) was obtained from Protein Data Bank 
(http://www.rcsb.org).  
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Molecular docking 
Molecular docking of quinazoline antifolate derivatives to the active 
site of human thymidylate synthase was carried out using modern 
docking engine LigandFit available with Cerius2_4.9. 
(http://www.accelrys.com). This algorithm makes use of a cavity 
detection algorithm for detecting invaginations in the protein as 
potential active site regions. A shape comparison filter is combined 
with a Monte Carlo conformational search for generating ligand poses 
consistent with the active site shape. Candidate poses are minimized in 
the context of the active site using a grid-based method for evaluating 
protein-ligand interaction energies. The docking was carried out with 
the following non default settings in LigandFit: site partitioning in 
order to fully access the potential docking orientation of the active site, 
maximum trials variable table values to help the pseudorandom 
conformational analysis, and the CFF force field [12] option used for 
the grid energy calculations. The flexible fitting option was selected 
for generation of alternative conformations on the fly, as was the 
diverse conformer's option to ensure the solutions generated cover a 
broad range of conformations with similar low-energy docking scores, 
and a maximum of 30 top scoring diverse ligand poses were returned 
for each of the compounds.  
 
Scoring function 
The docked conformations were further scored using different scoring 
functions available with Cerius2 [12]. The LigandFit algorithm [13] 
uses an internal scoring function, DockScore, to select and return 
dissimilar poses for each compound. DockScore is a simple force field 
based scoring function which estimates the energy of interaction by 
summing the ligand/protein interaction energy and the internal energy 
of the ligand. CFF force field [12] was used to resolve the van der 
Waals parameters for DockScore. The top DockScore pose was used 
for postdocking scoring. Scoring was performed using a set of scoring 
functions as implemented in Cerius2 [12]. These included LigScore1, 
LigScore2,-PLP1,-PLP2, - JAIN, PMF, LUDI and DockScore 
available from the docking process. The putative 3D poses and score 
results were then stored as an SD file. Each docking was minimized, 
using DockScore, the only purely molecular mechanics based scoring 
function employed in this study, and this minimized pose was then 
presented to each of the other scoring functions, which were either 
knowledge based or regression based.  
 
Protein preparation 
The high-resolution (2.50 A
o) X-ray structure of human thymidylate 
synthase complex with tomudex (PDBid code 1I00) was imported into 
Cerius2 [12], and the ligand was extracted to leave a cavity. Docking 
simulations were carried out with substrate dUMP and without water 
molecules, to elucidate the role of dUMP for the binding of 
quinazoline antifolate derivatives. 
 
Hardware and software 
Insight II 2000.1 [http://www.accelrys.com] and Cerius2 [12] were 
used for molecular modeling on a SGI Origin 300 workstation 
equipped with 4 * 600 Mhz R12000 processor. 
 
Results and Discussion: 
To date, several crystal structure of human thymidylate synthase in 
complex with different inhibitors have been reported viz 1I00 with 
ternary complex with dUMP and tomudex, [14], 1JUJ with dUMP 
LY231514, a pyrrolo(2,3-d)pyrimidine-based antifolate [15], 1JTQ 
with dUMP and the pyrrolo(2,3-d)pyrimidine-based antifolate 
LY341770 [15], 1JU6 with dUMP and LY231514, a pyrrolo(2,3-
d)pyrimidine-based antifolate [15], 1HVY with dUMP and  raltitrexed, 
an antifolate drug [16] etc. which provide information about the exact 
location and composition of inhibitor binding pocket and opportunity 
to use the enzyme in a functional conformation. We used X-ray 
structure of human thymidylate synthase in ternary complex with 
dUMP and tomudex (PDBid code 1I00) for the docking study. 
 
Validation of the docking method 
To ensure that the ligand orientation and the position obtained from 
the docking studies were likely to represent valid and reasonable 
binding modes of the inhibitors, the LigandFit program docking 
parameters had to be first validated for the crystal structure used 
(PDBid 1I00). The ligand tomudex, in the conformation found in the 
crystal structure, was extracted and docked back to the corresponding 
binding pocket, to determine the ability of LigandFit to reproduce the 
orientation and position of the inhibitor observed in the crystal 
structure. Results of control docking showed that LigandFit 
determined the optimal orientation of the docked inhibitor, tomudex to 
be close to that of the original orientation found in the crystal shown in 
Figure 1(a). The low RMS deviation of 0.290 Å between the docked 
and crystal ligand coordinates indicate very good alignment of the 
experimental and calculated positions especially considering the 
resolution of the crystal structure (2.50Å).  
 
Interaction modes between the quinazoline antifolate derivatives 
and human thymidylate synthase 
To study the binding modes of quinazoline antifolate derivatives in the 
binding site of human thymidylate synthase, intermolecular flexible 
docking simulations were performed by means of LigandFit program 
and Dockscores were calculated from the docked conformations of the 
human thymidylate synthase-inhibitor complexes. All the compounds 
in the dataset were docked into the active site of human thymidylate 
synthase, using the same protocol.  Thymidylate synthase monomer 
consists of an α/β–fold containing 7 α-helices and 10 β-strands, 
arranged in three layers :  a six stranded mixed β-sheet, a long α-helix 
across the sheet flanked by two shorter helices, and a mixed layer 
containing the remaining four helices and two antiparallel two-
stranded β-sheets. The large β-sheets from the monomers stack against 
each other to form dimer interface. The dimer contains two active 
sites, one within each monomer. The active site of human Thymidylate 
Synthase comprises of amino acids residues such as Arg50, Phe80, 
Leu 108, Asn112, Leu192, Asp218, Gly220, Leu221, Gly222, Phe225 
and Tyr258. As most of the amino acid residues in the active site are 
hydrophobic so they are involved in strong hydrophobic interactions 
with the quinozoline antifolate derivatives. It was depicts the aligned 
binding conformations of the quinazoline antifolate derivatives in the 
binding pocket of the human thymidylate synthase, which were 
derived from the docking simulations by LigandFit software. 
Molecular docking studies of quinozoline antifolate derivatives into 
human thymidylate synthase binding site revealed very clear 
preference for the binding pocket. All of the inhibitors occupy the 
binding site well as seen from the Figure 2. 
 
The majority of the contacts between the quinazoline antifolate 
derivatives and the protein are non polar, making use of the 
hydrophobic side chains in the binding site. Most of the quinazoline 
antifolate derivatives bind in more or less similar fashion with its 
quinazoline ring occupying the interior of the deep cleft and their tail 
is extended towards the entrance of the hydrophobic binding cavity. 
The quinazoline ring of quinazoline antifolate derivatives therefore 
bind to the human thymidylate synthase active site in an identical 
fashion, as reported in case of other inhibitors like tomudex [14] and 
raltitrexed  [16]. The quinazoline ring of the inhibitors forms 
hydrophobic contacts with Leu192, Leu221 and Tyr258. As seen from 
our docking studies the quinozoline core occupies the same core in the 
binding site as does the quinazoline ring of tomudex and makes 
stacking interaction with pyrimidine ring of UMP. This stacking 
interaction is very important and has been conserved in all the 
thymidylate synthases for with crystal structures has been solved in 
complex with the inhibitor and cofactor. Figure 1(b) represents the 
binding conformations of the highly active compounds, all of which 
share the common binding mode with quinazoline core occupy space 
deep in the cavity and ester tail extends towards the solvent.  
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The binding mode of the most active comp32 has been shown in 
Figure 1 (c). As expected, comp32 bind to the thymidylate synthase 
active site in the similar conformation as other known TS inhibitors 
(tomudex, ralitrexed etc.) which mainly bind using the quinazoline 
moiety and this moeity is presented to pyrimidine ring of cofactor 
UMP. This pterin ring is involved in π-π stacking interactions with the 
pyrimidine ring of UMP. This stacking interaction is very important 
and has been conserved in most the thymidylate synthases for which 
crystal structures have been solved with UMP and inhibitors in ternary 
complex with the enzyme. The amino group substituted at quinazoline 
ring of comp32 makes significant hydrogen bonding interaction with 
side chain oxygen of Tyr258 and sugar oxygen atom of cofactor UMP. 
So it can be concluded that the presence of a hydrogen bond donor 
group at 2-position of the quinazoline moiety is important for 
thymidylate synthase activity of the inhibitors. In addition to this 
important hydrogen bonding interaction quinazoline ring nitrogen N3 
and quinazoline carbonyl group make hydrogen bond with backbone 
oxygen of Asp218 and backbone nitrogen of Gly222 respectively. In 
addition to these hydrogen bonding interaction Comp32 is involved in 
van der Waals interactions through its phenyl ring with Ile108 and 
Phe225. Quinazoline ring is also involved in van der Waals 
interactions with the Trp109 (Residue not shown in figure for clarity) 
and Leu221 of the protein. Phe80 also show stacking interactions with 
the glutamyl chain of Comp32 and these particular interactions play 
very important role in thymidylate inhibition and need to be present 
for good inhibition by the inhibitors.  Comp32 shows all the 
interactions shown by the well known potent inhibitor tomudex of 
thymidylate and binds in almost the same fashion as tomudex do, 
however comp32 show additional hydrogen bonding interaction via –
NH2 substituted at quinazoline moiety (Figure 1(c) instead of tomudex 
which has methyl group substituted at this position.  
 
Figure  1: (a) Conformation of tomudex crystal structure (red) as compared to the docked conformation of tomudex (yellow) with cofactor 
substrate dUMP (atom color). Amino acid residues are presented by atom color, (b) Docked conformation highly active compounds (i) comp32 
(brown) (ii) comp47 (red) (iii) comp31 (orange) (iv) comp35 (yellow) (v) comp1 (green blue) (vi) comp52 (cyan) (vii) comp50 (light blue) (viii) 
comp34 (blue) (ix) comp37 (violet) (x) comp76 (magenta), (c) Docked confirmation of comp32 compared with binding  mode of tomudex, 1(d) 
Docked confirmation of comp13 compared with binding mode of tomudex and it shows the binding mode of least active comp13 and its 
comparison with the binding of tomudex. 
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Figure 2: A correlation for binding conformations and binding models of the quinazoline antifolate derivatives with human thymidylate synthase. 
 
Comp13 bind to thymidylate synthase active site in slightly tilted 
(about 45%) way when compared to the binding of highly active 
comp32 and crystal structure ligand tomudex. This particular tilt in the 
binding may be contributed by the absence of the hydrogen bonding 
amino group substituted at 2-position of the quinazoline ring. 
Additionally, this hydrogen bond positions the inhibitors for stacking 
interactions with the pyrimidine ring of the cofactor UMP. Loss or 
decrease in the stacking interaction may lead to decreased affinity for 
the protein binding site. The phenyl ring in comp13 is unsubstituted 
whereas flourine atom is substituted at 3-position of highly active 
comp32 which may lead to decreased van der Waals interactions with 
Ile108 and Phe225 and hence lead to decreased activity in case of 
comp13 and other inactive compounds. 
 
Correlation between docking scores and inhibitory activity 
An important application of LigandFit docking program in structure-
based drug design is to predict the inhibitory activities while 
determining the binding conformation of an inhibitor with the target 
by making use of their dock scores. Linear regression analysis 
analyses were performed to explore whether the docking scores could 
be correlated with the experimental activities. The predicted inhibitory 
activity of quinazoline antifolate derivatives as inhibitors on the basis 
of dock score is listed in Table 1 (see supplementary material). 
Linear regression analysis analyses were performed to explore whether 
the docking scores could be correlated with the experimental activities. 
The equation was obtained for the inhibitory activities represented as 
pIC50 values, using the Dock score, Ligscore1, Ligscore2, -PLP1, -
PLP2, JAIN, -PMF and Consensus score as the variable descriptors. A 
model with the correlation coefficient (r
2) of 0.148 was obtained for 
one hundred six compounds.Removal of 10 compounds (comp2, 
comp22, comp25, comp27, comp35, comp48, comp65, comp104, 
comp105, comp106) identified as outliers from the docking dataset 
yield a better model with correlation of coefficient (r
2) of 0.494 was 
obtained for ninety six compounds. This rather good correlation 
demonstrates that the binding conformations and binding models of 
the quinazoline antifolate derivatives with human thymidylate 
synthase are reasonable shown in Figure 2. 
 
Conclusion: 
The orientation of the quinazoline antifolate derivatives in the model 
complex is similar to that observed in the crystal structure. Despite 
some relaxation, due to the nature of the forcefield potentials, all 
important ligand-protein interactions are preserved during the energy 
minimization. Using the CVFF forcefield, the stacking interaction and 
hydrophobic contacts is very important in human thymidylate synthase 
complex with the quinazoline antifolate inhibitor and cofactor.  
 
  In this study, the molecular docking was applied to explore the 
binding mechanism and to correlate its docking score with the activity 
of a quinazoline antifolate derivatives. To our knowledge, this is the 
first study aimed at deriving docking studies for quinazoline antifolate 
derivatives. The docking studies provided good insights into the 
binding of quinazoline antifolate derivatives at the molecular level. 
Significant study between active sites and quinazoline antifolate 
derivatives will be analyzed to propose structural changes in these 
compounds, with the aim of rendering them more selective and 
thereby better human thymidylate synthase inhibitors.  
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Supplementary material: 
 
Table 1: Quinazoline antifolate derivatives with modifications 
Quinazoline antifolate derivatives with modifications 
 
HN
N R
1
O
CH2 N
R
2
O
NH
COOH
H
CH2CH2COOH
 
Derivative 
 
 
Position R
1 Position R
2
 
Experimental 
Activity 
(pIC50) 
Predicted 
Activity 
(pIC50) 
Residual 
DOCK 
SCORE 
Comp1 CH3 CH2C
 ≡CH  7.398 7.223  0.175  62.0985 
*Comp2  CH3 H  5.35  ********* *********  ********* 
Comp3  CH3 CH3 6.523 6.554  -0.031  74.1296 
Comp4  CH3 CH2CH3 6.77 6.417  0.353  70.5759 
Comp5  CH3 CH2CH=CH2 6.319 6.848  -0.529  54.0339 
Comp6  CH3 (CH2)2F  6.62 6.218  0.402  40.9059 
Comp7  CH3 (CH2)2Br  5.886 6.260  -0.374  55.3321 
Comp8  CH3 (CH2)2SH  5.754 6.261  -0.507  49.5824 
Comp9  CH3 (CH2)2OH  6.301 6.598  -0.297  79.1328 
Comp10  CH3 (CH2)3OH  6.268 5.477  0.791  34.8098 
Comp11  CH3 (CH2)2OCH3 4.789 5.661  -0.872  61.0809 
Comp12  CH3 (CH2)3OCH3 4.889 5.471  -0.582  41.3214 
Comp13  CH3 CH2COCH3 4.602 5.437  -0.835  42.7647 
Comp14 CH2CH3 CH2C
 ≡CH  6.854 6.353  0.501  56.3263 
Comp15 CH2CH3 H  4.699 5.504  -0.805  69.3533 
Comp16 CH(CH3)2 CH2C
 ≡CH  6.208 6.394  -0.186  50.3742 
Comp17 CH2F CH2C
 ≡CH  7.0 6.004  0.996  54.8555 
Comp18 CH2F CH3 5.535 5.297  0.238  56.1197 
Comp19 CH2F CH2CH3 6.432 6.801  -0.369  64.1659 
Comp20 CH2F (CH2)2F  6.469 6.573  -0.104  59.3171 
Comp21 CH2F CH2C
 ≡CH  6.237 6.744  -0.507  59.1139 
*Comp22 CF3 CH2C
 ≡CH  5.24  ********* *********  ********* 
Comp23  CH2OH  CH3 6.194 6.512  -0.318  62.7282 
Comp24  CH2OH  CH2CH3 6.585 6.836  -0.251  50.1905 
*Comp25  CH2OH  CH2CH=CH2 6.04  ********* *********  ********* 
Comp26  CH2OH  (CH2)2F  6.658 6.113  0.545  58.132 
*Comp27  CH2OH  (CH2)2OH  6.11  ********* *********  ********* 
Comp28 CH2NHCOCH3 CH2C
 ≡CH  6.319 6.057  0.262  68.6361 
Comp29 CH2S-2-pyrimidine CH2C
 ≡CH  6.62 6.990  -0.370  16.4223 
Comp30 Phenyl  CH2C
 ≡CH  6.658 5.994  0.664  44.0336 
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HN
N X
O
CH2 N
H2C
O
NH
COOH
H
CH2CH2COOH
C CH
Y
 
Position X  Position Y 
 
 
Comp31 NH2 H 7.699  6.729  0.970  76.5712 
Comp32 NH2 F 8.046  6.686  1.360  70.4486 
Comp33 H  H 6.77  6.784  -0.014  51.1791 
Comp34 H  F 7.237  7.100  0.137  70.4062 
*Comp35 CH3 F  7.7  ********* *********  ********* 
Comp36 CH2OH  H 7.009  6.959  0.050  63.9713 
Comp37 CH2OH  F 7.237  7.063  0.174  65.219 
Comp38 OCH3 H 7.167  6.498  0.669  71.557 
Comp39 OCH3 F 7.444  6.929  0.515  55.4344 
 
HN
N H3C
O
CH2 N
O
NH
COOH
H
CH2CH2COOH R
3' 2'
X
 
 
 
Position X  Position R 
      
Comp40  H H  5.347  6.337  -0.990  77.7392 
Comp41  H CH3 6.523 7.106  -0.583  61.9592 
Comp42  H CH2CH3 6.77 6.428  0.342  56.3273 
Comp43  H CH2CH=CH2 6.319 6.091  0.228  69.6427 
Comp44  H (CH2)2F 6.62  6.070  0.550  49.2357 
Comp45  H (CH2)2OH 6.301  6.703  -0.402  56.3914 
Comp46  H (CH2)3OH 6.268  6.591  -0.323  48.7268 
Comp47 2`-  F  CH2C
 ≡CH 7.699  7.199  0.500  60.0104 
*Comp48  2`- F  H  5.42  ********* *********  ********* 
Comp49  2`- F  CH3 6.921 6.160  0.761  77.1705 
Comp50 2`-  F  CH2CH3 7.347 6.503  0.844  70.4267 
Comp51  2`- F  CH2CH=CH2 7.119 6.965  0.154  41.9114 
Comp52  2`- F  (CH2)F 7.367  6.464  0.903  60.3416 
Comp53 2`-  F  (CH2)2OH 7.108  6.328  0.780  62.0603 
Comp54  2`- F  (CH2)3OH 6.229  6.074  0.155  53.2662 
Comp55  2`- F  (CH2)2NH2 4.931 5.808  -0.877  57.7233 
Comp56 2`-  F  CH2CN 6.77  6.058  0.712  53.4187 
Comp57  2`- F  CH2CONH2 5.873 6.144  -0.271  62.2975 
Comp58 3`-  F  CH2C
 ≡CH 5.845  5.933  -0.088  42.5697 
Comp59 3`-  F  H 5.03  6.085  -1.055  66.332 
Comp60 3`-  F  CH3 5.943 6.991  -1.048  65.3901 
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Comp61 3`-  F  CH2CH3 6.167 6.425  -0.258  60.914 
Comp62 3`-  F  CH2CH=CH2 5.287 6.050  -0.763  55.0781 
Comp63 3`-  F  (CH2)2F 5.757  6.293  -0.536  59.9575 
Comp64 3`-  F  (CH2)2OH 5.446  5.729  -0.283  55.404 
*Comp65 3`-  F  (CH2)3OH  6.01  ********* *********  ********* 
Comp66 2`-  Cl  CH2C
 ≡CH 7.131  6.818  0.313  59.7118 
Comp67 2`-  Cl  CH2CH3 6.921 6.024  0.897  57.9843 
Comp68 2`-  CF3 CH2C
 ≡CH 6.319  5.928  0.391  53.5381 
Comp69 2`-  CH3 CH2C
 ≡CH 6.301  6.513  -0.212  72.9112 
Comp70 2`-  CH3 CH3 6.027 6.416  -0.389  65.5774 
Comp71 2`-  CH3 CH2CH3 6.495 5.912  0.583  56.4926 
Comp72 2`-  NH2 CH2C
 ≡CH 6.538  6.437  0.101  61.8012 
Comp73 2`-  NH2 CH3 6.066 5.913  0.153  74.1392 
Comp74 2`-  NH2 CH2CH3 6.509 6.634  -0.125  67.3791 
Comp75 2`-  OH  CH2C
 ≡CH 7.046  7.218  -0.172  79.6766 
Comp76 2`-  OCH3 CH2C
 ≡CH 7.174  6.829  0.345  63.4102 
Comp77 2`-  OCH3 CH2CH3 6.721 7.250  -0.529  55.2489 
Comp78 2`-  NO2 CH2C
 ≡CH 6.886  5.945  0.941  52.9612 
Comp79 2`-  NO2 CH2CH3 6.84 6.226  0.613  47.4045 
 
HN
N H3C
O
CH2 N
R
O
NH
COOH
H
CH2CH2COOH
Ar
 
 
 
Position R  Position Ar 
      
Comp80 CH2C
 ≡CH 
S  
6.357 6.757  -0.400  54.2254 
Comp81 H 
S  
4.606 5.323  -0.717  69.7193 
Comp82 CH3
S  
6.174 6.413  -0.239  88.1727 
Comp83 CH2CH3
S  
6.237 6.089  0.148  65.42 
Comp84 (CH2)2CH3
S  
5.733 5.928  -0.195  27.2274 
Comp85 CH2CH=CH 
S  
5.755 6.137  -0.382  57.8916 
Comp86 (CH2)2F 
S  
6.26 6.377  -0.117  58.3581 
Comp87 (CH2)2OH 
S  
5.921 6.227  -0.306  68.9653 
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Comp88 (CH2)3OH 
S  
5.474 6.456  -0.982  67.2375 
Comp89 CH2CN 
S  
5.511 6.117  -0.606  70.8413 
Comp90 CH2C
 ≡CH 
N
S  
6.638 7.039  -0.401  56.7366 
Comp91 H 
N
S  
5.148 5.726  -0.578  77.5187 
Comp92 CH3
N
S  
6.377 5.844  0.533  76.4319 
Comp93 CH2CH3
N
S  
6.638 6.152  0.486  70.5299 
Comp94 CH2CH=CH2
N
S  
5.971 5.863  0.108  49.9632 
Comp95 (CH2)2F 
N
S  
6.721 6.714  0.007  52.658 
Comp96 (CH2)2OH 
N
S  
6.377 6.122  0.255  69.8192 
Comp97 (CH2)3OH 
N
S  
5.759 6.239  5.67  0.09 
Comp98 CH2CH3
N
S  
6.119 6.672  6.14  -0.02 
Comp99 CH2CH3
N N
S  
6.027 5.790  6.00  0.03 
Comp100 CH2C
 ≡CH 
N
 
7.398 6.506  7.18  0.22 
Comp101 CH3
N
 
6.456 6.150  5.61  0.85 
Comp102 CH2CH3
N
 
6.824 6.812  6.65  0.17 
Comp103 CH2CH=CH2
N
 
6.119 6.364  5.93  0.19 
*Comp104 (CH2)2F 
N
 
6.8  ********* *********  ********* 
*Comp105 CH3
N
 
5.37  ********* *********  ********* 
*Comp106 CH3
N
N  
5.63  ********* *********  ********* 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
* Outlier 
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